Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with regard to its clinical course. The limitations of the methods currently available for prognostic assessment in CLL do not allow accurate prediction of the risk of disease progression in individual patients. The recently developed cDNA array technique provides a unique opportunity to study gene expression in various malignancies. To identify new molecular markers for prognostication of CLL patients, we analyzed cDNA arrays by using hierarchical clustering and standard statistic t-test on 34 CLL patients. We found significant expression differences in 78 genes compared to the reference tonsillar B lymphocytes. A cluster of genes, LCP1, PARP, BLR1, DEK, NPM, MCL1, SLP76, STAM, HIVEP1, EVI2B, CD25, HTLF, HIVEP2, BCL2, MNDA,PBX3, EBI2, TCF1, CGRP, CD14, IL8,GZMK, GPR17 and CD79B, was associated (P < 0.05) with the unfavorable 11q deletion and also with the unfavorable Binet stages B and C. We present here gene expression profiling that is associated with CLL patients with the 11q23 deletion. Many of the genes in the cluster have not previously been shown to be related to the initiation or progression of CLL. These novel findings provide fundamental information for further attempts to understand the interaction of the clustered genes in the leukomogenesis of CLL in order to better design treatments aimed at specific molecular target(s).

[1]  S Woessner,et al.  Trisomy 12 in chronic lymphocytic leukemia: an interphase cytogenetic study. , 1991, Blood.

[2]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[3]  O. Kallioniemi,et al.  Frequent loss of the 11q14‐24 region in chronic lymphocytic leukemia: A study by comparative genomic hybridization , 1997, Genes, chromosomes & cancer.

[4]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[5]  N. Copeland,et al.  Evi-2, a common integration site involved in murine myeloid leukemogenesis , 1990, Molecular and cellular biology.

[6]  D. Kaufmann,et al.  EVI2B, a gene lying in an intron of the neurofibromatosis type 1 (NF1) gene, is as the NF1 gene involved in differentiation of melanocytes and keratinocytes and is overexpressed in cells derived from NF1 neurofibromas. , 1999, DNA and cell biology.

[7]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.

[8]  M. James,et al.  11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.

[9]  L. Benito,et al.  CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection , 1999, Leukemia.

[10]  E. Kieff,et al.  Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors , 1993, Journal of virology.

[11]  S. Kingsmore,et al.  The human myeloid cell nuclear differentiation antigen gene is one of at least two related interferon-inducible genes located on chromosome 1q that are expressed specifically in hematopoietic cells. , 1994, Blood.

[12]  E. Wolf,et al.  A Putative Chemokine Receptor, BLR1, Directs B Cell Migration to Defined Lymphoid Organs and Specific Anatomic Compartments of the Spleen , 1996, Cell.

[13]  F. Alt,et al.  Impaired Viability and Profound Block in Thymocyte Development in Mice Lacking the Adaptor Protein SLP-76 , 1998, Cell.

[14]  S. Molica,et al.  Surface CD14 positivity in B‐cell chronic lymphocytic leukaemia is related to clinical outcome , 1999, British journal of haematology.

[15]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[16]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[17]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.

[18]  R. Miranda,et al.  Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. , 1999, Human pathology.

[19]  A. de la Chapelle,et al.  Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. , 1986, The New England journal of medicine.

[20]  C Stratowa,et al.  CDNA microarray gene expression analysis of B‐cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking , 2001, International journal of cancer.

[21]  A. Chan,et al.  Identification of Two Tyrosine Phosphoproteins, pp70 and pp68, Which Interact with Phospholipase Cγ, Grb2, and Vav after B Cell Antigen Receptor Activation* , 1997, The Journal of Biological Chemistry.

[22]  K. Franssila,et al.  Deletions at 11q23 in different lymphoma subtypes. , 2000, Haematologica.

[23]  N. Tanaka,et al.  STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction. , 1997, Immunity.

[24]  P. O'Connell,et al.  cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene. , 1991, Genomics.

[25]  J. McGillis,et al.  A role for calcitonin gene related peptide (CGRP) in the regulation of early B lymphocyte differentiation. , 1995, Canadian journal of physiology and pharmacology.

[26]  S. Knuutila,et al.  Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia , 1999, Leukemia.

[27]  S. Fernandez,et al.  Calcitonin‐gene related peptide (CGRP) inhibits interleukin‐7‐induced pre‐B cell colony formation , 2000, Journal of leukocyte biology.

[28]  H. Gralnick,et al.  Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. , 1989, Journal of clinical pathology.

[29]  N. Nagy,et al.  LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. , 1999, Immunology letters.

[30]  F. Collin,et al.  Implication of the Epstein-Barr virus in the progression of chronic lymphocytic leukaemia/small lymphocytic lymphoma to Hodgkin-like lymphomas. , 1997, Anticancer research.

[31]  S. Knuutila,et al.  Optimized mitogen stimulation induces proliferation of neoplastic B cells in chronic lymphocytic leukemia: significance for cytogenetic analysis , 1998, Cytogenetic and Genome Research.

[32]  R. Foà,et al.  Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. , 1996, Blood.